{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-012748","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.624562+00:00","generated_at":"2026-06-06T05:47:16.927824+00:00","sec_items":["1.01","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revelation Biosciences raises $6.2M in public offering, regains Nasdaq bid price compliance","bullets":["Gross proceeds ~$6.2M from sale of 128,470 shares and 1,236,530 pre-funded warrants, plus 2,730,000 Class D warrants at $4.53 combined price.","Class D warrants exercisable at $4.53/share, expire in 5 years; pre-funded warrants at $0.0001/share, no expiration.","Net proceeds to fund Phase 1a/1b studies for GEM-SSI (surgical site infection) and GEM-AKI (cardiac surgery AKI), plus preclinical GEM-CKD work.","Nasdaq confirmed on Feb 8, 2024 that REVB regained compliance with minimum $1.00 bid price rule after 11 consecutive trading days above $1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-012748","json":"https://secwatch.observer/filing/0000950170-24-012748.json","markdown":"https://secwatch.observer/filing/0000950170-24-012748.md","text":"https://secwatch.observer/filing/0000950170-24-012748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/revb-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:47:16.927824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"327ab6f3a5223ca330954b301fb578d3aee1f7be","claim":"REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"gross proceeds of approximately $6.2 million"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"},{"claim_id":"aae76ad83daf1a60142b9d53931480cd8abaea9c","claim":"REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).","evidence_excerpt":"On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) 128,470 shares of its common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants to purchase 1,236,530 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying two warrants to purchase 2,730,000 shares of Common Stock (the “Class D Common Stock Warrants”) at a combined offering price of $4.53 per share of Common Stock and associated two Class D Common Stock Warrants, or $4.5299 per Pre-Funded Warrant and associated two Class D Common Stock Warrants, resulting","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024012748/0000950170-24-012748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"gross proceeds of approximately $6.2 million"},{"label":"Effective","value":"2024-02-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}